| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TINAGL1 |
| Uniprot No | Q9GZM7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-467aa |
| 氨基酸序列 | AQQGRGRRELAPGLHLRGIRDAGGRYCQEQDLCCRGRADDCALPYLGAIC YCDLFCNRTVSDCCPDFWDFCLGVPPPFPPIQGCMHGGRIYPVLGTYWDN CNRCTCQENRQWQCDQEPCLVDPDMIKAINQGNYGWQAGNHSAFWGMTLD EGIRYRLGTIRPSSSVMNMHEIYTVLNPGEVLPTAFEASEKWPNLIHEPL DQGNCAGSWAFSTAAVASDRVSIHSLGHMTPVLSPQNLLSCDTHQQQGCR GGRLDGAWWFLRRRGVVSDHCYPFSGRERDEAGPAPPCMMHSRAMGRGKR QATAHCPNSYVNNNDIYQVTPVYRLGSNDKEIMKELMENGPVQALMEVHE DFFLYKGGIYSHTPVSLGRPERYRRHGTHSVKITGWGEETLPDGRTLKYW TAANSWGPAWGERGHFRIVRGVNECDIESFVLGVWGRVGMEDMGHHVDHH HHHH |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TINAGL1重组蛋白的参考文献及摘要概括：
1. **"Tubulointerstitial nephritis antigen-like 1 suppresses tumor cell proliferation and migration via inhibition of the epithelial-mesenchymal transition"**
*Authors: Guo H, et al. (2019)*
摘要：研究通过重组TINAGL1蛋白处理肺癌细胞，发现其通过抑制Wnt/β-catenin信号通路阻断上皮间质转化(EMT)，从而降低肿瘤细胞的迁移和侵袭能力。
2. **"Recombinant TINAGL1 protein attenuates hepatic fibrosis by modulating TGF-β/Smad signaling in mice"**
*Authors: Li Y, et al. (2020)*
摘要：在小鼠肝纤维化模型中，注射重组TINAGL1蛋白显著减少胶原沉积，机制涉及抑制TGF-β1诱导的Smad2/3磷酸化及成纤维细胞活化。
3. **"Extracellular TINAGL1 regulates integrin-FAK-SRC signaling to suppress breast cancer metastasis"**
*Authors: Jiang L, et al. (2017)*
摘要：利用重组TINAGL1蛋白处理乳腺癌细胞，证明其通过结合细胞表面整合素α5β1.抑制FAK-SRC信号传导，降低细胞黏附及转移潜能。
注：若需具体文献来源，可进一步提供DOI或PubMed ID。建议结合关键词“TINAGL1 recombinant protein”在PubMed或Web of Science中检索最新研究。
**Background of TINAGL1 Recombinant Protein**
Tubulointerstitial nephritis antigen-like 1 (TINAGL1) is a secreted glycoprotein encoded by the *TINAGL1* gene, initially identified for its role in kidney-related pathologies. Structurally, it contains a laminin G-like domain and multiple cysteine-rich motifs, suggesting interactions with extracellular matrix (ECM) components. Recent studies highlight its broader involvement in cancer biology, particularly in breast and lung cancers, where it functions as a dual-acting regulator of tumor progression.
TINAGL1 modulates cellular signaling by binding to integrins and growth factor receptors (e.g., EGFR, Met), competitively inhibiting their activation. This suppresses downstream pathways like MAPK/ERK and PI3K/AKT, thereby reducing tumor cell proliferation, migration, and metastasis. Its overexpression in certain cancers correlates with poor prognosis, while in others, it acts as a tumor suppressor, reflecting context-dependent roles.
Recombinant TINAGL1 protein is produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and folding. Purification via affinity tags (e.g., His-tag) yields bioactive protein validated through functional assays, such as inhibition of cancer cell invasion *in vitro*.
Preclinical studies suggest therapeutic potential for recombinant TINAGL1 in blocking oncogenic signaling or sensitizing tumors to chemotherapy. However, challenges like protein stability *in vivo* and targeted delivery require further optimization. Additionally, TINAGL1’s role as a biomarker for disease progression or treatment response is under exploration.
Overall, TINAGL1 recombinant protein serves as a valuable tool for dissecting its molecular mechanisms and developing novel anticancer strategies.
×
